XJPX
8129
Market cap1.51bUSD
Oct 09, Last price
3,687.00JPY
1D
0.35%
1Q
-7.03%
Jan 2017
58.10%
IPO
896.49%
Name
Toho Holdings Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Toho Holdings Co., Ltd. serves as a leading wholesaler of pharmaceutical and healthcare products throughout Japan. Its extensive product range includes prescription and over-the-counter medications, reagents, medical devices and supplies, and health foods, in addition to offerings for preventive, clinical, community, and home-based medical and nursing care. Beyond distribution, the company provides comprehensive support services like developing and selling customer-focused software, assisting with the establishment of new medical facilities and pharmacies, delivering management consulting, offering medical assistance, and facilitating personnel recruitment. Toho Holdings also operates dispensing pharmacies, manufactures and distributes generic drugs, acts as a site management organization (SMO) to support clinical trials for various healthcare institutions, and supplies specialized software to the medical sector. Among its technological solutions are customer support systems such as ENIF for pharmaceutical ordering, ENI-Pharmacy for streamlining dispensing and prescribing processes, LXMATE HeLios for medical appointments, KAITOS for online medical consultations and medication guidance, ENIFwin for inventory control in large hospitals, the ENIFvoice series for voice-activated electronic medication history recording, and ENIF Nurse for home-visit nurse operational support, along with diverse logistics systems. The company, founded in 1948, is headquartered in Tokyo, Japan.
Key people
Takeo Matsutani
Chairman of Subsidiary, Director · since 2023
Makoto Kawamura
Managing Executive Officer, Chief Director of Business Strategy, Director of Business Planning · since 2025
Tsuguo Nakagomi
Managing Executive Officer, Chief Director of Logistics and System Planning, President of Subsidiary · since 2025
Takashi Kobayashi
Executive Officer, Chief Director of General Affairs and Human Resources, Director of General Affairs, Manager of Secretary's Office · since 2025
Satoshi Ikeda
Executive Officer · since 2021
Aya Komai
Executive Officer, Director of Pharmajoy Tokyo, Assistant Manager of Pharmaceutical Affairs Supervision Unit · since 2023
Shigeki Nakata
Executive Officer · since 2021
Aiko Noshiro
Executive Officer, Director of Public Relations in Main Public Relations and International Relations · since 2023
Kengo Ogawa
Executive Officer · since 2019
Yasuo Sakae
Chief Financial Officer, Executive Officer · since 2025
Kazuki Shimizu
Executive Officer, Deputy Chief Director in Main Business Strategy Unit, Director of Group Governance · since 2025
Kazuyuki Watanabe
Executive Officer · since 2022
Hiromi Edahiro
Chief Executive Officer, Chief Financial Officer, Representative Director · since 2024
Shuzo Kono
Executive Officer, President of Subsidiary, Director · since 2025
Kentaro Murakawa
Director · since 2022
Masami Tada
Senior Director of Pharmaceutical Affairs, Manager of Quality Assurance Office, Director · since 2022
Akira Umada
Senior Managing Executive Officer, Chief Operating Officer, President of Subsidiary, Director · since 2025
Chie Goto
Independent Director · since 2024
Manako Haga
Independent Director · since 2025
Yoshiaki Kamoya
Independent Director · since 2020
Headquarters & legal address
代沢四丁目43番11号
東京都 世田谷区 155-8655
JP
東京都 世田谷区 155-8655
JP
Address
43-11,Daizawa 4-chome
Setagaya-ku Tokyo 155-8655
JP
Setagaya-ku Tokyo 155-8655
JP
Other language
TOHO HOLDINGS CO.,LTD.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||